REG - Faron Pharma. Oy - Exercise of options

Faron Pharmaceuticals OyAnnouncement

01/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220601:nRSA4747Na&default-theme=true

RNS Number : 4747N  Faron Pharmaceuticals Oy  01 June 2022

Faron Pharmaceuticals Ltd.

("Faron")

 

Exercise of options

Issue of equity

 

Company announcement, June 1, 2022 at 07:00 am BST / 9:00 am EEST

 

TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd. (AIM: FARN, First
North: FARON), a clinical stage biopharmaceutical company focused on building
the future of immunotherapy by harnessing the power of the immune system to
tackle cancer and inflammation, announces that it has received notifications
from option holders to exercise 2015D options over 25,000 shares in the
Company at an exercise price of EUR 1.09 (approx. GBP 0.93) per share under
the Company's 2015 Option Plan ("New Ordinary Shares"). The terms and
conditions of the 2015 Option Plan are available on the Company's website at
https://www.faron.com/sites/default/files/Option%20Plan%202015_Terms%20and%20Conditions_20200518.pdf
(https://www.faron.com/sites/default/files/Option%20Plan%202015_Terms%20and%20Conditions_20200518.pdf)
.

 

Applications have been made to the London Stock Exchange and Nasdaq Helsinki
to admit the New Ordinary Shares to trading on AIM and Nasdaq First North
Growth Market, respectively. Admission of the New Ordinary Shares is expected
to occur on or around June 7, 2022 following issue and registration of the New
Ordinary Shares on or around June 6, 2022 ("Registration"). The New Ordinary
Shares will rank pari passu with existing ordinary shares.

 

Faron's enlarged issued number of shares immediately following Registration
will be 53,257,032 ordinary shares with voting rights attached. The Company
has no shares in treasury; therefore upon, and subject to, Registration, the
total number of voting rights in Faron will be 53,257,032. This figure may be
used by shareholders as the denominator for the calculations by which they
will determine whether they are required to notify an interest in, or a change
to their interest in, the issued shares and votes of the Company.

 

For more information please contact:

 

Investor Contact

Faron Pharmaceuticals

Julia Balanova

VP, Investor Relations

julia.balanova@faron.com (mailto:julia.balanova@faron.com)

investor.relations@faron.com (mailto:investor.relations@faron.com)

Phone: +1 (917) 306-6096

 

Media Contact

Faron Pharmaceuticals

Eric Van Zanten

VP, Communications

eric.vanzanten@faron.com (mailto:Eric.vanzanten@faron.com)

Phone: +1 (610) 529-6219

 

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

 

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

 

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

 

Consilium Strategic Communications

Mary-Jane Elliott, David Daley, Lindsey Neville

faron@consilium-comms.com (mailto:faron@consilium-comms.com)

Phone: +44 (0)20 3709 5700

 

About Faron Pharmaceuticals Ltd.

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical
company developing novel treatments for medical conditions with significant
unmet needs caused by dysfunction of our immune system. The Company currently
has a pipeline based on the receptors involved in regulation of immune
response in oncology, organ damage and bone marrow regeneration. Bexmarilimab,
a novel anti-Clever-1 humanized antibody, is its investigative precision
immunotherapy with the potential to provide permanent immune stimulation for
difficult-to-treat cancers through targeting myeloid function. Currently in
Phase I/II clinical development as a potential therapy for patients with solid
tumors and hematologic malignancies, bexmarilimab has potential as a
single-agent therapy or in combination with other standard treatments
including immune checkpoint molecules. Traumakine is an investigational
intravenous (IV) interferon beta-1a therapy for the treatment of acute
respiratory distress syndrome (ARDS) and other ischemic or hyperinflammatory
conditions. Traumakine is currently being evaluated by the 59th Medical Wing
of the US Air Force and the US Department of Defense for the prevention of
multiple organ dysfunction syndrome (MODS) after ischemia-reperfusion injury
caused by a major trauma.  Faron is based in Turku, Finland. Further
information is available at www.faron.com (http://www.faron.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEDFLFXLELXBBX